571 POSTER Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor von Olsen, C.E, Gourley, E.S, Liu, X, Vankayalapati, H, Vollmer, D, Severson, P, Bearss, J, Jones, C, Bearss, D.J, Warner, S.L

Volltext

234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 von Friedlander, M.L., Moore, K., Colombo, N., Scambia, G., Kim, B-G., Oaknin, A., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Banerjee, S., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W., Holmes, E., Lowe, E.S., Disilvestro, P.

Volltext

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 von Banerjee, S., Moore, K.N., Colombo, N., Scambia, G., Kim, B-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Oza, A., Martín, A. González, Aghajanian, C., Bradley, W., Holmes, E., Lowe, E.S., DiSilvestro, P.

Volltext

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial von Moore, K.N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Banerjee, S., Oza, A.M., González-Martín, A., Aghajanian, C., Bradley, W., Lowe, E.S., Bloomfield, R., DiSilvestro, P.

Volltext

Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated wit... von Oaknin, A., Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Banerjee, S., Oza, A.M., González-Martín, A., Aghajanian, C., Bradley, W., Lowe, E.S., Bloomfield, R., DiSilvestro, P.

Volltext

995PD - Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) tre... von Oaknin, A., Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Banerjee, S., Oza, A.M., González-Martín, A., Aghajanian, C., Bradley, W., Lowe, E.S., Bloomfield, R., DiSilvestro, P.

Volltext

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial von Friedlander, M., Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Banerjee, S., Oza, A.M., González-Martín, A., Aghajanian, C., Bradley, W., Lowe, E.S., Bloomfield, R., Disilvestro, P.

Volltext